We serve Chemical Name:6-(chloromethyl)-1-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one CAS:931075-55-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![6-(chloromethyl)-1-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one](https://a.dearchem.com/CAS2/931075-55-7.png)
Chemical Name:6-(chloromethyl)-1-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one
CAS.NO:931075-55-7
Synonyms:6-(chloromethyl)-1-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one
Molecular Formula:C7H7ClN4O
Molecular Weight:198.61000
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.671g/cm3
Index of Refraction:1.743
PSA:63.57000
Exact Mass:198.03100
LogP:0.39540
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 6-(chloromethyl)-1-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-(chloromethyl)-1-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-(chloromethyl)-1-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one Use and application,6-(chloromethyl)-1-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one technical grade,usp/ep/jp grade.
Related News: In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. 6-(chloromethyl)-1-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one manufacturer The Philippines reported its first Wuhan coronavirus fatality on Sunday. 6-(chloromethyl)-1-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one supplier INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. 6-(chloromethyl)-1-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one vendor INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. 6-(chloromethyl)-1-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one factory But even though weight-loss success depends on adopting a challenging” change in post-operation diet and lifestyle, the process can certainly “help people to lose weight and get comorbid [other negative health] conditions under better control,” Sandon said.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies.
